再生元制药公司宣布其降胆固醇药物Praluent将可通过特朗普政府推出的Trumprx.gov平台实现患者直接采购。这一举措标志着处方药销售模式的重大变革，患者无需经过传统医疗机构中转即可获得该创新疗法。
通过政府主导的数字化采购平台，Praluent的可及性将得到显著提升。作为PCSK9抑制剂类药物的代表产品，该药物主要用于治疗他汀类药物控制不佳的高胆固醇血症患者。直接面向消费者的销售模式突破传统药品流通壁垒，为患者提供更便捷的用药途径。
此项合作体现了制药企业与政府医疗创新项目的深度协同。在医疗数字化浪潮下，药品流通环节的简化有望降低整体医疗成本，同时保障药品供应链的稳定性。对于需要长期用药的心血管疾病患者而言，这种新型采购渠道将大幅提升治疗便利性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.